The Global leader in metabolomics

Advance GLP-1 Therapeutic Discovery and Development with Industry-Leading Metabolomics

Metabolomics delivers a comprehensive understanding of the metabolic changes induced by GLP-1 receptor agonists, uncovering novel mechanisms of action, identifying predictive and pharmacodynamic biomarkers, and generating evidence to support therapeutic label expansion into new indications and patient populations.

Metabolomics delivers critical mechanistic insights into the actions of GLP-1 receptor agonists and SGLT2 inhibitors (SLGT2i), enabling researchers to precisely track biochemical and metabolic pathway changes induced by these therapies, including the regulation of glucose, insulin and energy homeostasis. By mapping drug-induced metabolic signatures and identifying predictive pharmacodynamic biomarkers, metabolomics can reveal novel therapeutic targets, improve drug efficacy, and enhance patient stratification strategies. In conjunction, this system-level view of metabolism can support safer, more personalized treatment approaches, potentially accelerating timelines and reducing costs across the drug development cycle. With industry-leading technology, deep scientific expertise, and a proven track record in multiomics integration, Metabolon empowers GLP-1 and SGLT2i research teams to move from data to decision faster, aiding in the goal of driving promising therapies toward clinical and commercial success.